GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies

The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market

Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers

Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development

Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab

SPARC announces consolidation of R&D laboratories and facilities

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations

Briefs: Zydus, Divi's Laboratories and Relonchem

FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations

Caplin Point Laboratories’ subsidiary acquires land in Mexico

The investment in land is Rs. 19.85 crore

Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg

Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology